Otsuka Holdings
4578.T
#674
Rank
NZ$51.77 B
Marketcap
$96.12
Share price
-0.60%
Change (1 day)
65.27%
Change (1 year)
Otsuka Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company involved in the R&D of drugs and healing methods for respiratory diseases, eye diseases, cardiovascular diseases, neurological and mental diseases as well as Parkinson's, tuberculosis and cancer.

Revenue for Otsuka Holdings (4578.T)

Revenue in 2024 (TTM): NZ$23.74 Billion

According to Otsuka Holdings 's latest financial reports the company's current revenue (TTM ) is NZ$25.59 Billion. In 2023 the company made a revenue of NZ$22.44 Billion an increase over the revenue in the year 2022 that were of NZ$20.52 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Otsuka Holdings from 2010 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$23.74 B5.78%
2023 NZ$22.44 B9.39%
2022 NZ$20.52 B4.77%
2021 NZ$19.58 B5.32%
2020 NZ$18.59 B-2.25%
2019 NZ$19.02 B8.98%
2018 NZ$17.45 B12.28%
2017 NZ$15.54 B-1.91%
2016 NZ$15.85 B-9.37%
2015 NZ$17.49 B
2013 NZ$17.22 B-0.96%
2012 NZ$17.39 B-5.2%
2011 NZ$18.34 B10.96%
2010 NZ$16.53 B